Is There a Role for Therapeutic Drug Monitoring of Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease

被引：6

作者：

Baert, Filip ^{[1
]}

机构：

[1] AZ Delta, Dept Gastroenterol, BE-8800 Roeselare, Belgium

来源：

DIGESTIVE DISEASES | 2015年 / 33卷

关键词：

Anti TNF monoclonal antibody; Trough concentration; Anti-drug antibody; Immunogenicity; Therapeutic drug monitoring; CROHNS-DISEASE; INFLIXIMAB TREATMENT; SERUM INFLIXIMAB; DOSE INTENSIFICATION; CLINICAL-RESPONSE; ADULT PATIENTS; LOST RESPONSE; TROUGH LEVELS; ADALIMUMAB; PHARMACOKINETICS;

D O I：

10.1159/000437078

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

In recent years it has become clear that therapeutic drug monitoring can be an important tool to optimize outcome and costs of anti TNF treatment including the subcutaneous and fully human monoclonal antibodies. There is a clear dose response curve between early serum concentrations of all monoclonal antibodies and response both short term and long term. The wide variations in early serum concentrations are insufficiently explained by classic pharmacokinetic factors. Low early concentrations can lead to anti-drug antibody formation and ensuing loss of response. Therapeutic drug monitoring allows to rationalize the current practice of dose optimization and the use of concomitant immunomodulator treatment. However more prospective studies are needed before strong recommendations can enter treatment guidelines. (C) 2015 S. Karger AG, Basel

引用

页码：70 / 77

页数：8

共 59 条

[1] Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease [J].

Afif, Waqqas ;

Loftus, Edward V., Jr. ;

Faubion, William A. ;

Kane, Sunanda V. ;

Bruining, David H. ;

Hanson, Karen A. ;

Sandborn, William J. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (05) :1133-1139

[2]

[Anonymous], 2013, UNITED EUR GASTROENT, V1, pA1

[3]

Arias MT, 2012, J CROHNS COLITIS S1, V6, pS5

[4]

Awni WM, 2013, GASTROENTEROLOGY, V144, pS229

[5] Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy [J].

Baert, Filip ;

Drobne, David ;

Gils, Ann ;

Vande Casteele, Niels ;

Hauenstein, Scott ;

Singh, Sharat ;

Lockton, Steve ;

Rutgeerts, Paul ;

Vermeire, Severine .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) :1474-U352

[6] Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease [J].

Ben-Horin, Shomron ;

Waterman, Matti ;

Kopylov, Uri ;

Yavzori, Miri ;

Picard, Orit ;

Fudim, Ella ;

Awadie, Halim ;

Weiss, Batia ;

Chowers, Yehuda .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (04) :444-447

[7] Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab [J].

Bendtzen, Klaus ;

Geborek, Pierre ;

Svenson, Morten ;

Larsson, Lotta ;

Kapetanovic, Meliha C. ;

Saxne, Tore .

ARTHRITIS AND RHEUMATISM, 2006, 54 (12) :3782-3789

[8] Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies [J].

Bendtzen, Klaus ;

Ainsworth, Mark ;

Steenholdt, Casper ;

Thomsen, Ole Ostergaard ;

Brynskov, Jorn .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (07) :774-781

[9] Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review [J].

Billioud, Vincent ;

Sandborn, William J. ;

Peyrin-Biroulet, Laurent .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (04) :674-684

[10] Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays [J].

Casteele, N. Vande ;

Buurman, D. J. ;

Sturkenboom, M. G. G. ;

Kleibeuker, J. H. ;

Vermeire, S. ;

Rispens, T. ;

van der Kleij, D. ;

Gils, A. ;

Dijkstra, G. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (08) :765-771

← 1 2 3 4 5 6 →